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CLINICAL INVESTIGATION
Increased renal tubular expression of transforming growth factor
beta in human allografts correlates with cyclosporine toxicity
OLEH G. PANKEWYCZ, Li MlAo, Ross Iscs, JING GUAN, TIM PRUErT, GAIL HAUSSMANN,
and B.C. STURGILL
Department of Medicine, Health Sciences Center, University of Virginia, Charlottesville, Virginia, USA
Increased renal tubular expression of transforming growth factor beta
in human allografts correlates with cyclosporine toxicity. Cyclosporine A
(CsA) is a potent immunosuppressive drug that inhibits the transcription
of several proinflammatory cytokines including interleukin-2. In contrast,
CsA stimulates transcription of the pleuripotent cytokine, transforming
growth factor-/3 (TGFp). Since the effect of CsA in transplant recipients is
unpredictable, we examined whether tissue levels of TGFI3 protein in
renal allografts correlate with in viva CsA responsiveness. Intra-allograft
TGFI3 protein content was assessed in renal biopsies by immunohisto-
chemical means using the mouse anti-TGF monoclonal antibody (Mab),
1D11. We studied 68 specimens: 21 with acute CsA toxicity (ACT), 11 with
acute tubular necrosis (ATN) and 36 with acute cellular rejection (ACR).
intensity of TGFf3 immunostaining was evaluated in a blinded fashion
using a scale from 0 to 3+. In biopsies with histological evidence of CsA
toxicity, 77% demonstrated intense (2 to 3+) TGF/3 immunostaining.
TGFI3 protein was detected in both proximal and distal tubules hut was
either absent or present in low levels within glomeruli and interstitium. In
contrast, only one of the 11 biopsies with ATN had minimal staining (1+)
for TGF(. The remaining 10 biopsies with ATN were negative for TGF
immunostaining. In biopsies with ACR, the levels of renal TGFI3 were
more variable with 36% showing intense (2 to 3+) staining and 64%
having minimal or no (0 to 1+) tubular TGFI3. Within the first 18 months
post-transplantation, patients with intense TGFP staining and ACR
underwent an average of 4.1 1.8 allograft biopsies and suffered 33%
graft losses. During the same period of time, the patients with ACR and
absent or low (0 to 1+) TGFJ3 levels underwent only 2.1 1.2 biopsies,
maintained better late renal function and suffered 4% graft losses. In
conclusion, we demonstrate that TGF/3 protein levels in renal allografts
correlate with CsA effect and differentiate ACT from ATN. In CsA
treated patients who develop ACR, TGF levels predict the subsequent
clinical course and graft function. Therefore, evaluating tissue levels of
TGFI3 may offer unique diagnostic and prognostic benefits in the care of
patients receiving CsA based immunosuppression.
Incorporation of cyclosporine A (CsA) into therapeutic immu-
nosuppressive protocols has led to a remarkable improvement in
the survival rates of solid organ transplants. In the American and
European populations, CsA therapy led to an increase in the
percentage of patients maintaining a functioning cadaveric renal
allograft at five years by 11% and 17%, respectively [1, 21. Most of
the benefit of CsA centers about the prevention of acute rejection
episodes [3]. Despite its potent immunosuppressive properties,
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clinical application of CsA in transplantation is limited by its
unpredictable nephrotoxic potential [4].
CsA is associated with a variety of clinically and histologically
defined alterations in renal allograft function [5, 6]. Acute CsA
toxicity (ACT) is manifested clinically by a functional decrease in
the glomerular filtration rate which rapidly improves following a
reduction in the CsA dose [7, 81. In the immediate post-transplant
period, differentiating this hemodynamically mediated form of
cyclosporine toxicity from acute tubular necrosis (ATN) can pose
a significant clinical problem. Since renal ischemia is a significant
risk factor for both ACT and ATN, recipients of cadaveric
allografts have the potential to suffer from either disorder or a
combination of both [9]. Insofar as clinical tests fail to distinguish
between these clinical entities, many centers withhold CsA ther-
apy until cadaveric allograft function is firmly established [9—11].
This therapeutic strategy necessitates the use of prophylactic
anti-lymphocyte directed antibody therapies to avoid early acute
rejection episodes [12]. The use of polyclonal or monoclonal
antilymphocyte immunoglobulins significantly increases the over-
all risks and costs of transplantation. Therefore, an assay measur-
ing CsA effects in vivo would be a useful clinical tool in the
post-transplant setting.
A second important manifestation of CsA toxicity is chronic
CsA induced nephrosclerosis. Prolonged use of CsA causes a well
recognized histologic form of chronic nephrotoxicity character-
ized by interstitial "striped" fibrosis and tubular atrophy [13—16].
These pathological changes also occur in the native kidneys of
liver and heart transplant recipients as well as in patients with
autoimmune disorders treated with CsA [14, 17]. Chronic CsA
toxicity may be progressive leading to the development of end-
stage renal disease (ESRD) [15, 18]. More recently however,
Burke et al reported that renal transplant function remains stable
despite continuous CsA therapy [31. The pathogenesis and prog-
nosis of CsA induced renal fibrosis remain controversial.
Although several risk factors for the development of CsA
toxicity have been identified, it is well appreciated that individual
susceptibility to CsA effects remains unpredictable [5, 19—22].
Indeed, the incidence of acute cellular rejection (ACR) in CsA
treated patients may be as high as 46% [3]. Variations in CsA
efficacy and toxicity amongst transplant recipients may be due to
individual differences in CsA tolerance and responsiveness [5].
Such in vivo disparities in CsA effects cannot simply be predicted
by CsA blood levels [1, 6, 23, 24]. Therefore, therapeutic CsA
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blood levels do not guarantee an effective level of immunosup-
pression nor safety from GsA nephrotoxicity. An alternative
approach to defining CsA effects in vivo would be to measure the
individual renal tissue response to CsA.
Evidence obtained from both humans and animal models shows
that CsA directly increases the production of the cytokine trans-
forming growth factor-a (TGFJ3) [25—29]. This potent CsA effect
on TGFf3 transcription and secretion has been observed in vitro in
human T lymphocytes, mouse proximal tubular cell lines and
tubulointerstitial fibroblasts as well as in vivo in mouse and rat
kidneys. To date, no correlation has been made between CsA
therapy, expression of TGFI3 and clinical outcome [30]. To this
end, we have examined intrarenal levels of TGFI3 in allograft
biopsies obtained from patients suffering from acute cellular
rejection (ACR), acute cyclosporine toxicity (ACT) and acute
tubular necrosis (ATN). We demonstrate that tissue levels of
TGF/3 correlate with CsA effect and differentiate ACT and ATN.
Moreover, in CsA treated patients undergoing ACR intra-al-
lograft levels of TGFI3 predict subsequent renal function. These
results have clinical implications and potential applications in CsA
directed immunosuppression.
Methods
Tissue samples
All transplant renal biopsies performed at the University of
Virginia between 1989 and 1996 were screened retrospectively for
pathological diagnosis. The pathological diagnoses were initially
determined from the historical attending physician final reports.
Biopsies previously diagnosed as predominantly demonstrating
changes consistent with ACT, ACR or ATN were used in this
study. Sixty eight biopsies obtained from 53 different patients
fulfilled these criteria and were included in this study. In order to
confirm the diagnosis, each biopsy was reviewed in a blinded
fashion by a single experienced pathologist (B.C.S.). Biopsies
demonstrating ACR were scored for severity according to a
modified Banif Classification scheme as borderline, mild, moder-
ate or severe [311. Acute CsA toxicity was characterized by an
absence of lymphocytic infiltrates, tubulitis or ATN with minor
tubular abnormalities including vacuolization. Acute tubular ne-
crosis was characterized by an absence of lymphocytic infiltration
and loss of epithelium or flattening and dilation with tubular cell
regeneration and mitotic figures. No biopsy demonstrated trans-
plant glomerulopathy, chronic allograft rejection or chronic cyclo-
sporine toxicity.
Tissue preparation
Previously cut formalin fixed and paraffin embedded tissue
sections were obtained from the University of Virginia Renal
Biopsy Tissue Files. Tissue content of TGF was assessed in an
indirect immunoperoxidase method utilizing a mouse pan-specific
anti-TGFf3 monoclonal antibody (Mab), 1DI1 (Celtrix Corp.,
Palo Alto, CA, USA). The specificity of this antibody has been
previously described [321.
Tissue sections were deparaffinized in xylenc and rehydrated in
graded ethanol to phosphate-buffered saline (PBS) (0.15 M NaCI,
0.02 M P04, pH 7.2). Endogenous pcroxidase activity was blocked
for 30 minutes in a methanol/peroxide (18:1 vol/vol ratio) solu-
tion. Nonspecific binding was blocked with 1.5% Avidin/Biotin
(Vector Labs, Burlingame, CA, USA) diluted in a solution
containing 10% normal horse serum (Sigma, St. Louis, MO, USA)
and 3% bovine serum albumin (BSA; Sigma) in PBS (HBP) for
one hour. The tissue sections were then interacted overnight at
4°C with 1D1 I Mab (50 xg/rnl) in HBP. Following extensive
washing in PBS, the slides were first incubated with a biotin
labeled anti-mouse IgG horse antiserum (1:1000 dilution; Vector
Labs) in HBP for one hour at RT, extensively washed in PBS and
then in the ABC solution for 30 minutes (Vector Labs). The slides
were then developed for 10 minutes in diaminobenzidine (DAB;
Vector) and water rinsed for 15 minutes. The slides were coun-
terstained with hematoxylin followed by dehydration in graded
ethanol and xylene. The slides were mounted with Permount for
evaluation.
To ensure uniformity between experiments, samples from all
three diagnostic groups were included in each individual experi-
ment. The color reaction was held constant for each sample within
a given experiment. All tissue examinations and grading for
intensity of TGF/3 staining were performed in a blinded fashion by
a single experienced pathologist (B.C.S.). The intensity of immu-
noperoxidase staining was reported in a graded fashion from 0 =
no staining to 3+ = very intense staining.
Clinical data
Clinical information was obtained from medical records and
transplant clinic charts. To remove bias in the study, clinical
outcome criteria (graft loss, number biopsies and serum creati-
nine) were analyzed for each patient independent of any knowl-
edge of immunoperoxidase staining results. Blood CsA drug levels
(ng/ml) (TDX) were measured by standard commercial RIA
techniques at the time of biopsy.
Statistics
Results are reported as the mean SD. Data were analyzed by
ANOVA, Fisher PLSD, chi-square analysis and unpaired two-
tailed Student's t-test. Predictability was assessed using Pearson
R2 value with alpha set at 0.05.
Results
Patient demographics
Sixty-eight allograft biopsies obtained from 53 different patients
were identified (Table 1). The biopsy diagnoses included 21 with
ACT, ii with ATN and 36 with ACR. There were no differences
among the groups in terms of age at transplant, sex, race, percent
of patients with diabetes or type of renal transplant.
Except for one patient who presented six years after transplant
with dehydration and an elevated serum creatinine, the time to
biopsy was much shorter in the groups with ATN and ACR
compared to the ACT group. Due to large variability in values, the
time to biopsy in the ATN and ACR groups was similar. Ten of
the eleven biopsies with ATN were obtained from patients who
had initially nonfunctional grafts and required early renal biopsy
to differentiate established ATN from developing ACR.
Among the three groups of biopsies, there were no differences
in the serum CsA levels (TDX) obtained at the time of biopsy. Of
the 11 biopsies with ATN, 4 were obtained from patients who
were receiving no CsA at the time of biopsy. These 4 patients were
excluded from the TDX analysis.
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Table 1. Baseline characteristics of the study groups
Characteristics
Acute CsA
toxicity(N 21)
Acute tubular
necrosis
(N = 11)
Acute cellular
rejection(N = 36)
P
value
Age years 42 16 40 14 44 16 0.74
Male sex 71 73 69 0.94
Race %
White 67 82 69 0.73
Black 33 18 31
Diabetes % 38 36 28 0.70
Type of transplant %
Cadaveric 62 55 67 0.44
Living related 24 9 19
Kidney-pancreas 14 36 14
Time to first biopsy 5.4 6.1 0.6 0.4 2.9 3.5 0.014a
months
CsA plasma level 365 287 285 121 346 182 O.7O
Plus-minus values are means SD. N is the number of biopsies.
a One patient in the ATN group presented 6 years after transplant and
was excluded from analysis, and thus, the mean time to first biopsy value
in the ATN group was calculated based on ten patients; P < 0.05 ACT vs.
ATN and ACR; P = NS ATN vs. ACR.
b Four patients with ATN were not receiving CsA and were excluded
from analysis. Therefore, the mean TDX level in the ATN group was
based on the values obtained in the remaining seven patients.
lmmunocytochemistiy
Representative examples of the different intensities of tissue
immunoperoxidase staining for TGFI3 are shown in Figure 1.
Positive staining for TGFf3 was most prominently observed within
renal tubules. There was occasional mild staining of the intersti-
tium especially in patients with hemorrhagic rejection. The gb-
meruli uniformly appeared negative. When compared to negative
samples under higher magnification, positive samples demon-
strated both proximal and distal tubular staining for TGFJ3 (Fig.
2). TGF/3 was present within tubules showing vacuolar degener-
ation and in normal appearing tubules.
The combined results of TGF/3 staining for all three diagnostic
groups are shown in Table 2. TGF expression was higher in
biopsies with ACT compared to both the ATN or ACR groups
(P < 0.001). The differences in intensity of TGFf3 staining were
most striking between the ACT and ATN groups. Only one of the
11 biopsies with ATN contained TGFI3 protein which was present
in only minimal amounts. In contrast, TGFJ3 was expressed in all
21 biopsies with ACT. Moreover, 77% of biopsies with ACT
demonstrated intense (2 to 3+) staining for TGFI3. TGF expres-
sion in biopsies with ACR was more evenly distributed between
the minimal or no staining categories (0 to 1+; 64%) and the
intense (2 to 3+; 36%) categories.
CsA blood levels failed to correlate with intensity of intra-
allograft TGF(3 immunostaining (P = 0.64). Moreover, in the
ACR group, TDX values were no different between those with
intense (360 177 ng/ml) and minimal (337 188 nglml) renal
allograft TGF staining. Therefore, TDX levels did not correlate
with histological diagnosis (ACT, ATN or ACR) and did not
differentiate among patients with ACR.
To examine whether intrarenal TGFI3 levels simply reflected
the degree of allograft dysfunction at the time of biopsy, the
intensity of TGFI3 staining was compared to the serum creatinine
(Fig. 3). Biopsies were divided into those obtained from patients
with good (creatinine <2.0 mg%), moderate (creatinine 2.0 to 3.3
mg%) and poor allograft function (creatinine > 3.3 mg%; P <
0.001). There was no difference in the intensity of TGF/3 staining
between biopsies performed in patients with good renal function
(Group 1, N = 19, creatinine 1.5 0.3 mg/dl, TGFI3 intensity
1.1 1.1), moderate renal dysfunction (Group 2, N = 28,
creatinine 2.6 0.4, TGFI3 intensity 2.1 2.0) or severe renal
failure (Group 3, N = 21, creatinine 5.0 2.1, TGFf3 intensity
0.9 1.2; P = 0.08). There was no direct correlation between
degree of TGFI3 staining intensity and serum creatinine (P =
0.49).
Clinicopathological correlations in patients with ACR
As noted above, patients with ACR could be classified into two
distinct categories according to the degree of intrarenal TGFI3
expression. Patients had either minimal amounts of renal TGFJ3
(N = 24; 0 to 1+) or intense renal TGFJ3 content (N = 12; 2 to
3+). In this group of patients, the level of renal TGFI3 expression
failed to correlate with the severity of acute rejection (P =0.76).
Heavy TGFI3 expression was observed in only 22% of ACR
biopsies of moderate severity, 40% of those with minimal severity
and 50% of those with borderline severity. Our previous correla-
tion between renal TGFI3 levels and biopsy evidence of CsA
toxicity suggests that in certain patients acute cellular rejection
may occur despite significant CsA tissue effects.
To determine if there were any consequences to having both
high intrarenal TGFJ3 levels and ACR, the clinical outcomes of
patients with ACR and minimal (0 to 1+) or intense (2 to 3+)
TGF staining were compared (Fig. 4). Although there was no
difference in the 1/serum creatinine (mg/dl) values between the
two groups two weeks after transplantation (42 21 vs. 53 24,
P = 0.23), patients with intense staining had a lower level of renal
function at one month (35 17 vs. 60 25, P < 0.01), three
months (45 18 vs. 65 22, P < 0.05), six months (43 15 vs.
63 22, P < 0.05), 12 months (36 13 vs. 62 21, P < 0.01) and
18 months (36 12 vs. 56 16, P < 0.05) after transplant. Of the
patients with minimal TGFI3 staining only I of 24 patients lost
their graft to rejection. A greater percentage of patients with
intensely positive TGF/3 staining returned to dialysis within 18
months (4 of 12, P < 0.05). Over the same period of time,
post-transplant patients with ACR and minimal TGFJ3 staining
had fewer renal biopsies per patient (1.9 0.9) than did their
counterparts with intense staining (4.1 1.7; P < 0.001). At all
time points measured, the level of intrarenal TGFI3 expression
positively predicted an inferior clinical outcome (Pearson R2, P <
0.05).
Discussion
CsA remains fundamental to the induction of therapeutic
immunosuppression following renal transplantation. Although its
utility in preventing of acute rejection and in prolonging allograft
survival is well documented, CsA-induced nephrotoxicity contin-
ues to be an important limitation [3]. Refinements in measuring
CsA blood levels have improved medical therapy and CsA dosing
[6, 23]. Despite these advances, many CsA treated patients will
still undergo at least one episode of acute cellular rejection [31.
Thus, among individual transplant patients CsA blood levels do
not ensure an adequate level of immunosuppression. Such indi-
vidual susceptibility to CsA may be partly due to unpredictable
variations in in vivo drug responsiveness and drug tolerance.
This study was conducted to explore the possibility that in
human transplant recipients, TGF levels within renal allograft
tissues reflect the in vivo responsiveness to CsA. For this purpose,
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Fig. 1. Representative examples of TGFI3 immunostaining intensities (low magnification). Photographs were taken from biopsies stained for TGFI3
simultaneously in one experiment. A. Negative TGFI3 immunostaining of a renal biopsy obtained from a patient with ATN (X200). B. 1+ TGF/3
immunostaining of a renal biopsy obtained from a patient with ACT (x200). C. 2+ TGFI3 immunostaining of a renal biopsy obtained from a patient
with ACT (x200). D. 3+ TGF/3 immunostaining of a renal biopsy obtained from a patient with ACT (X200).
Fig. 2. Representative examples of TGFI3 immunostaining intensities (high magnification). A. Negative TGFI3 immunostaining of a renal biopsy obtained
from a patient with ACR. Proximal and distal tubules have no TGFJ3 Content. B. 2+ TGFI3 immunostaining of a renal biopsy obtained from a patient
with ACT. Both proximal (large arrows) and distal (small arrows) demonstrate the presence of TGFf3.
an immunocytochemical assay for tissue TGFI3 was developed patients with three different clinical scenarios: acute CsA toxicity,
utilizing the panspecific anti-TGFf3 mouse Mab, 1DI1. We exam- acute tubular necrosis and acute cellular rejection. Intense stain-
med renal tissue biopsy specimens obtained from transplant ing for TGFp could be observed within proximal and distal renal
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Table 2. Intensity of renal biopsy TGF/3 staining by
immunoperoxidasea
Acute Acute
Acute CsA tubular cellular
TFGI3 toxicity necrosis rejection
intensity = 21) (N = 11) (N = 36)
0 0/21 (0%) 10/11(91%) 12/36 (33%)
1+ 5/21 (23%) i/lI (9%) 12/36(33%)
2+ 5/21 (23%) 0/11 (0%) 6/36(17%)
3+ 11/21 (54%) 0/11 (0%) 6/36(17%)
Semiquantitative analysis of TGFP protein expression in renal biopsies.
For each biopsy sample, renal expression of TGFI3 was scored from 0 to
3+ and correlated with diagnosis as noted in the attending pathologist's
final report and confirmed in a blinded fashion by a single pathologist.
Results are given as number of biopsies of a given intensity within each
diagnostic catagory (percentages). N is the number of biopsies.a < 0.001
tubules. TGF staining was minimal or completely absent from
the glomeruli, interstitium and lymphocytic infiltrates. The inten-
sity of tubular TGFI3 staining was most prominent in biopsies
containing typical histological changes of CsA toxicity and high,
but not necessarily toxic, CsA blood levels. In biopsies with ATN,
renal tubular TGFI3 was notably absent. Moreover, in the four
patients with ATN who were not being treated with CsA TGFj3
staining was uniformly negative. Although these findings are
correlative, the results strongly suggest that CsA induces human
allograft tubular expression of TGF/3.
Rather than being a direct CsA effect, the expression of tubular
TGFf3 could be due to tubular reabsorption of filtered cytokine.
Although possible, this alternate possibility is less likely since
circulating and urinary levels of TGFJ3 were shown not to be
elevated during episodes of acute CsA toxicity [30]. Alternatively,
renal tubular TGFI3 expression could have been due to renal
damage or dysfunction. However, in this study, the degree of renal
tubular expression of TGF failed to correlate with serum creat-
mine levels at the time of biopsy. Other factors that were
irrelevant to TGF/3 expression were age, sex, race, type of
transplant or the presence of diabetes. Thus, in the immediate
post-transplant period, renal TGFI3 content may aid in differen-
tiating acute CsA toxicity from primary graft non-function or
other causes of ATN.
CsA blood levels proved unreliable in predicting clinical toxicity
or response to therapy. TDX levels failed to discriminate biopsies
with ACT from those with ATN or ACR. Moreover, 26 of the 36
biopsies with acute cellular rejection were harvested from patients
with adequate blood levels of CsA (TDX > 250 ng/ml). Thus, a
given individual's renal allograft TGF/3 content could not be
predicted with confidence from the TDX.
When analyzed for outcome, the level of allograft TGFI3
content in patients with ACR proved to be a strong predictor of
late renal function. Moreover, patients with ACR and intense
TGF/3 staining had more complicated clinical courses as demon-
strated by the increased number of renal biopsies performed in
this patient subpopulation. Since we avoided examining biopsies
obtained from patients with chronic rejection and chronic CsA
toxicity (striped fibrosis), the decrease in late renal function was
not due to progressive renal scarring. Rather it is possible that the
presence of high intrarenal TGFJ3 levels during ACR is a marker
of more intense immunological processes that cannot be arrested
Fig. 3. Correlation of TGFI3 immunostaining with allograft function. Biopsy
samples were grouped into 3 eatagories according to serum creatinine
values at the time of biopsy: Group 1, creatinine < 2.0 mg%; Group 2,
creatinine 2.0 to 3.3 mg%; and Group 3, creatinine > 3.3 mg%. Symbols
are: (U) serum creatinine; () intensity of TGF staining. Results are
depicted as mean SD. P = NS amongst Groups 1, 2, and 3. P < 0.05
Group 2 versus Groups I and 3. tP < 0.05 Group 3 versus Group 1.
by adequate or even toxic tissue effects of CsA. Such rejection
episodes would tend to recur and over time result in a greater
degree of renal injury. Indeed, even one ACR episode correlated
with decreased allograft survival [3]. Thus, in the late post-
transplant period, renal TGFf3 content may aid in identifying a
patient population undergoing ACR with a poor ultimate out-
come. It remains to be defined whether this subpopulation would
benefit from modifications in immunosuppressive therapy.
Defining the optimal CsA dose and timing of administration
continues to be a significant clinical dilemma. To define the
mechanisms of CsA toxicity and efficacy, recent investigations
have focused on designing appropriate animal models. It is now
becoming increasingly recognized that in vivo CsA directly in-
duces TGFI3 expression. In a rat model of acute CsA toxicity,
increased TGFI3 protein expression was noted in juxtaglomerular
cells as well as in afferent and interlobular arterioles [29]. Pichler
et al reported that in a rat model of chronic CsA toxicity with
renal scarring, there was an increase in interstitial staining for
TGFI3 [33]. Since CsA induces TGFI3 expression in rodent tubular
cells in vitro, and tubular cells are a potential rich source of TGFI3
in vivo, the reason for negative tubular staining in these animals is
not entirely clear [25, 34]. Given the well recognized species
differences in CsA responses, the discrepancy in these findings
may be due to an increased resistance of rat tubules to CsA effects
[35]. In a previous study of human allografts with acute and
chronic rejection, TGFJ3 protein expression was observed in
glomeruli and interstitial areas [27]. Since fibrosis and scarring are
late events, the lack of tubular staining in these patients with
chronic rejection may be related to timing of the biopsy. More-
over, the lack of tubular TGFI3 staining in this study may be
related to CsA levels which were not defined [271. Alternatively,
our findings may be due to the use of different primary reagents to
detect allograft TGF/3 expression. Using the same monoclonal
anti-TGF/3 antibody (1DII), previous investigators were unable
to correlate blood or urine TGFI3 levels with clinical diagnosis or
outcome [30]. Thus, assessing tissue levels of TGFI3 protein as
detected by the Mab, IDI 1, potentially offers unique advantages
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Fig. 4. Clinical outcome in patients with A CR
and low versus high intro-graft TGFI3 expression.
Patients with ACR were classified into either a
negative or low TGFI3 expressing group (0 to
1 + staining, U) or a high TGF expressing
group (2 to 3+, LI). The 1/serum ereatinine
values were plotted versus time at two weeks,
one month, three months, six months, 12
months and 18 months after transplantation.
Numbers below the graph indicate the number
of patients at risk for both groups at the various
time points (mean SE). * < 0.05 between
groups.
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